GBM primary cell lines, derived from NULU and ZAR patients, exhibit an unmethylated profile of the MGMT gene promoter and, consequently, a drug-resistance phenotype to conventional TMZ chemotherapy. This evidence concerns the gene MGMT and glioblastoma.